166 related articles for article (PubMed ID: 35845536)
1. Systemic glucocorticoid-free therapy with adalimumab plus immunosuppressants versus conventional therapy in treatment-naïve Vogt-Koyanagi-Harada disease patients.
Yang S; Tao T; Li Z; Chen B; Huang Z; Liu X; Li H; Xie L; Feng W; Su W
Ann Transl Med; 2022 Jun; 10(12):699. PubMed ID: 35845536
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy.
Yang S; Tao T; Huang Z; Liu X; Li H; Xie L; Wen F; Chi W; Su W
Front Med (Lausanne); 2021; 8():799427. PubMed ID: 35096888
[No Abstract] [Full Text] [Related]
3. Clinical and Transcriptional Profiles Reveal the Treatment Effect of Adalimumab in Patients with Initial-Onset and Recurrent Vogt-Koyanagi-Harada Disease.
Guo K; Xu X; Yang F; Wang K; Zhang X
Ocul Immunol Inflamm; 2024 May; ():1-11. PubMed ID: 38709230
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab treatment for chronic recurrent Vogt-Koyanagi-Harada disease with sunset glow fundus: A multicenter study.
Takeuchi M; Nakai S; Usui Y; Namba K; Suzuki K; Harada Y; Kusuhara S; Kaburaki T; Tanaka R; Takeuchi M; Mizuki N; Nakai K; Goto H; Herbort CP
Saudi J Ophthalmol; 2022; 36(4):380-386. PubMed ID: 36618573
[TBL] [Abstract][Full Text] [Related]
5. Early post-treatment choroidal thickness to alert sunset glow fundus in patients with Vogt-Koyanagi-Harada disease treated with systemic corticosteroids.
Hirooka K; Saito W; Namba K; Mizuuchi K; Iwata D; Hashimoto Y; Ishida S
PLoS One; 2017; 12(2):e0172612. PubMed ID: 28241069
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy of Adalimumab as an Initial Treatment in Patients with Behçet's Retinal Vasculitis.
Yang S; Huang Z; Hu Y; Zhang J; Liu X; Li H; Xie L; Wen F; Liang D; Su W
Front Pharmacol; 2021; 12():609148. PubMed ID: 34239438
[No Abstract] [Full Text] [Related]
7. Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.
Couto C; Schlaen A; Frick M; Khoury M; Lopez M; Hurtado E; Goldstein D
Ocul Immunol Inflamm; 2018; 26(3):485-489. PubMed ID: 27775450
[TBL] [Abstract][Full Text] [Related]
8. Outcome and Prognostic Factors of Phacoemulsification Cataract Surgery in Vogt-Koyanagi-Harada Uveitis.
Ji Y; Hu K; Li C; Li P; Kijlstra A; Eghrari AO; Lei B; Du L; Wan W; Yang P
Am J Ophthalmol; 2018 Dec; 196():121-128. PubMed ID: 30194930
[TBL] [Abstract][Full Text] [Related]
9. Changes in Central Macular Thickness and Retinal Nerve Fiber Layer Thickness in Eyes with Vogt-Koyanagi-Harada Disease: A 2-Year Follow-Up Study.
Han YS; Shin KS; Lee WH; Kim JY
Ophthalmologica; 2018; 239(2-3):143-150. PubMed ID: 29339644
[TBL] [Abstract][Full Text] [Related]
10. The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.
Park UC; Cho IH; Lee EK; Yu HG
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1203-1211. PubMed ID: 28382438
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy.
Takayama K; Obata H; Takeuchi M
Ocul Immunol Inflamm; 2020 Apr; 28(3):509-512. PubMed ID: 31268769
[No Abstract] [Full Text] [Related]
12. Evaluation of microvasculature alterations in convalescent Vogt-Koyanagi-Harada disease using optical coherence tomography angiography.
Fan S; Lin D; Hu J; Cao J; Wu K; Li Y; Liu R; Dai ML; Bao Z; Wang Y
Eye (Lond); 2021 Jul; 35(7):1993-1998. PubMed ID: 33024324
[TBL] [Abstract][Full Text] [Related]
13. Vogt-Koyanagi-Harada is a Curable Autoimmune Disease: Early Diagnosis and Immediate Dual Steroidal and Non-Steroidal Immunosuppression are Crucial Prerequisites.
Papasavvas I; Tugal-Tutkun I; Herbort CP
J Curr Ophthalmol; 2020; 32(4):310-314. PubMed ID: 33553831
[TBL] [Abstract][Full Text] [Related]
14. Predictive Biomarker for Progression Into the Sunset Glow Fundus of Vogt-Koyanagi-Harada Disease, Using Adaptive Binarization of Fundus Photographs.
Komuku Y; Ishikawa H; Ide A; Matsuoka T; Fukuyama H; Okadome T; Gomi F
Transl Vis Sci Technol; 2020 Oct; 9(11):10. PubMed ID: 33133773
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature.
Rahman N; Artiaga JCM; Bouras K; Luis J; Rees A; Westcott M
J Ophthalmic Inflamm Infect; 2023 May; 13(1):27. PubMed ID: 37204477
[TBL] [Abstract][Full Text] [Related]
16. Corticotherapy vs. Corticotherapy Plus Immunosuppressive Therapy in Acute Vogt-Koyanagi-Harada Disease.
Concha-Del Río LE; Gómez L; Arellanes-García L
Arch Soc Esp Oftalmol (Engl Ed); 2018 May; 93(5):225-230. PubMed ID: 29258782
[TBL] [Abstract][Full Text] [Related]
17. The Steroid-Sparing Effect of Adalimumab in the Treatment for the Recurrent Phase of Vogt-Koyanagi-Harada Disease.
Shinagawa M; Namba K; Mizuuchi K; Iwata D; Hase K; Suzuki K; Hirooka K; Kitaichi N; Hiraoka M; Ishida S
Ocul Immunol Inflamm; 2023 Apr; 31(3):501-505. PubMed ID: 35212595
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behçet's uveitis with vasculitis.
Yang S; Huang Z; Liu X; Li H; Xie L; Chen X; Wen F; Liang D; Su W
Int Immunopharmacol; 2021 Apr; 93():107430. PubMed ID: 33581500
[TBL] [Abstract][Full Text] [Related]
19. VKH disease in the elderly: Variations in clinical course as compared to VKH disease in adults.
Kaza H; Cherukuri N; Tyagi M; Basu S; Pappuru RR; Murthy S
Indian J Ophthalmol; 2024 Jan; ():. PubMed ID: 38189444
[TBL] [Abstract][Full Text] [Related]
20. A clinical grading system based on ultra-wide field retinal imaging for sunset glow fundus in Vogt-Koyanagi-Harada disease.
Lee EK; Lee SY; Yu HG
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):359-68. PubMed ID: 25017008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
